Urology - urothelial cancer, Malmö
161 – 170 of 172
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
(
- Contribution to journal › Article
-
Mark
Second-look resection for primary stage T1 bladder cancer : a population-based study
(
- Contribution to journal › Article
-
Mark
Intravesical instillations and cancer-specific survival in patients with primary carcinoma in situ of the urinary bladder
(
- Contribution to journal › Article
-
Mark
Molecular classification of urothelial carcinoma : global mRNA classification versus tumour-cell phenotype classification
(
- Contribution to journal › Article
-
Mark
Long-term functional outcomes after radical cystectomy with ileal bladder substitute : does the definition of continence matter?
(
- Contribution to journal › Article
-
Mark
A randomized comparison between league tables and funnel plots as an aid to health care decision-making
(
- Contribution to journal › Article
- 2016
-
Mark
Re : Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Stage T1 Bladder Cancer – Aspects of Diagnosis and Treatment
2016)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective : results from a prospective intervention study
(
- Contribution to journal › Article